Drugs /

idelalisib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
idelalisib
Trade Name(s):
Zydelig
NCI Definition [1]:
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for idelalisib

Idelalisib has been investigated in 8 clinical trials, of which 7 are open and 1 is closed. Of the trials investigating idelalisib, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).

CD19 Expression is the most frequent biomarker inclusion criterion for idelalisib clinical trials.

Follicular lymphoma, acute lymphoblastic leukemia, and acute myeloid leukemia are the most common diseases being investigated in idelalisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Idelalisib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Idelalisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating idelalisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cal-101, gs-1101, Zydelig, pi3k delta inhibitor cal-101, idelalisib (product), gs 1101, idelalisib (substance), phosphoinositide-3 kinase delta inhibitor cal-101, cal 101, phosphoinositide-3 kinase delta inhibitor cal-101, 5-fluoro-3-phenyl-2-((s)-1-(9h-purin-6-ylamino)-propyl)-3h- quinazolin-4-one, idelalisib, 5-fluoro-3-phenyl-2-((s)-1-(9h-purin-6-ylamino)-propyl)-3h-quinazolin-4-one, cal101, 5-fluoro-3-phenyl-2-([s)]-1-[9h-purin-6-ylamino]-propyl)-3h-quinazolin-4-one, pi3k-delta inhibitor cal-101, idelalisib, 5-fluoro-3-phenyl-2-[(1s)-1-(3h-purin-6-ylamino)propyl]quinazolin-4(3h)-one
Drug Categories [2]:
PI3K inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
PIK3CD
NCIT ID [1]:
C78825
SNOMED ID [1]:
F-D2602

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.